banner
 
bar

program

slides
bar
 
 

Optimizing Cardiovascular Risk Reduction in Type 2 Diabetes

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period September 25, 2012 through September 25, 2014 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all five segments totaling 1 hour and 13 minutes to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.

Estimated Time to Complete Educational Activity

1.5 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in cardiovascular risk reduction in the setting of diabetes and acute coronary syndrome.

Release Date

September 25, 2012

Expiration Date

September 25, 2014

Intended Audience

This program is intended for all cardiologists, endocrinologists, diabetes specialists, and other healthcare professionals who treat patients with diabetes and/or acute coronary syndrome.

Registration

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

logo This CME activity is supported by an
educational grant from Roche.

Physician Continuing Education

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The University of Massachusetts Medical School designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Disclosure of Conflicts of Interest

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity, and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials

Program Faculty and Disclosure

Distinguished Program Co-Chair
A. MICHAEL LINCOFF, MD

Vice Chairman, Department of Cardiovascular Medicine
Cleveland Clinic
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio USA

Consultant: AstraZeneca, Avanir, Edwards Lifesciences, Ikaria (Data Safety Monitoring Committee), Roche, Merck/Schering-Plough
Research Funding: Aastrom, Anthera, AstraZeneca, BMS, Cardiovascular Systems, Centocor, Edwards Lifesciences, Eli Lilly (Principal Investigator), Ethicon, J & J, Juventas, Kai Pharmaceutical (Principal Investigator), Karo Bio, Medtronic, Merck/Schering-Plough (National Coordinator), Novartis, Orexigen, Pfizer (Co-Principal Investigator), Regado, Reserverlogix, Roche (Principal Investigator), Sanofi-aventis, Scios, Takeda (Principal Investigator), VIVUS (Principal Investigator)



Distinguished Program Co-Chair
GILLES MONTALESCOT, MD, PhD

Professor of Cardiology
Institut de Cardiologie
Hôpital la Pitie-Salpêtrière
Paris, FRANCE

Consultant: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eli Lilly and Company; GlaxoSmithKline; Menarini Group; Nanosphere, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Portola Pharmaceuticals, Inc.; sanofi-aventis; The Medicines Company
Research Support: Received grants for clinical research from: Abbott Laboratories; AstraZeneca Pharmaceuticals; Boston Scientific; Bristol-Myers Squibb Company; Cordis Corporation; Eli Lilly and Company; Guerbet; ITC, Edison, NJ; Medtronic, Inc.; Pfizer; sanofi-aventis; SERVIER; Stago



JORGE PLUTZKY, MD
Associate Professor of Medicine
Harvard Medical School
Director, The Vascular Disease Prevention Program
Brigham and Women's Hospital
Boston, Massachusetts, USA

Consultant: Abbott, Amylin Pharmaceuticals, BMS, Daiichi Sankyo, GSK, Merck, Novo Nordisk, Orexigen, Pfizer, Roche/Genentech, Takeda, Vivus


PHILIPPE GABRIEL STEG, MD, FESC, FACC
Director, Coronary Care Unit
Hôpital Bichat-Claude Bernard
Professor of Cardiology
University Paris VII
Paris, FRANCE

Consultant: Eisai, GlaxoSmithKline, Otsuka, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol–Myers Squibb, Daiichi Sankyo, Medtronic, Merck Sharp & Dohme, Novartis
Speaker’s Bureau: The Medicines Company
Grant/Research Support: SERVIER, Sanofi
Shareholder: Aterovax

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  • Understand the scientific and clinical research dimensions of ongoing investigations assessing the role of novel agents that may lower cardiovascular (NSTE-ACS and MI), and stroke risk, in the setting of high-risk T2DM, especially after ACS and in the setting of CAD.
  • Describe the rationale and potential clinical impact of therapeutic strategies based on new mechanisms of action, involving dual peroxisome proliferator-activated receptor-alpha/gamma (PPAR) agonism, on cardiometabolic markers, including lipids, HA1c, glucose levels, and their impact on cardiovascular disease.
  • Implement vasculopathy-mitigating therapies that work through lipid and glycemic regulation as well as other insulin-related mechanisms, including insulin resistance in order to reduce the incidence of cardiovascular mortality, nonfatal myocardial infarction and stroke in patients with type 2 diabetes and CAD; especially in high-risk patient populations with a history of an ACS event and multiple associated with risk factors.
  • Apply strategies that address atheroinflammatory processes and that make an impact on the vasculopathic cascade that characterizes T2DM and predisposes to macrovascular disease and its cardiovascular complications.
  • Implement strategies that are effective for residual risk reduction and secondary prevention of adverse thromboembolic events in the setting of diabetes after acute coronary syndrome (ACS); and, address the need for multi-factorial, multi-parameter risk management of cardiometabolic interfaces that increase CV risk in T2D patients who have ACS.

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to printout the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2012 by Pharmatecture, LLC and CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.


bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC and Pharmatecture, LLC

 
6

 

Key Program Topics Include:

ACCORD
ACS
Acute Coronary Syndrome
Adipocytes
Adiponectin
ALECARDIO
Aleglitazar
Aleglitazar
AMI
atherogenesis
Atherogenicity
Atherosclerotic Heart Disease
Atherothrombosis
BARI 2D Trial
Cardiometabolic
CHD
Clopidogrel
coronary heart disease

DCCT
Diabetes
Dual PPAR Agonists
dyslipidemia
Euro-Heart Survey
fenofibrate
Fibrate
FIELD
FPG
gemfibrozil
GIK
GLP-1
Glycemic Control
HbA1c
HDL,
HDL-C
Helsinki Heart Study
Hyperglycemia
Hyperglycemic

Insulin
ISAR-DIABETES
LDL
LDL-C
Lipid
MACE
Macrovascular
Muraglitazar
PERISCOPE
Peroxisome Proliferator-activator Receptors
Pioglitazone
PPAR
AMI
PPARa
PPARg
PPARd
PPAR-g agonism
Prasugrel

PROactive
Retinopathy Progression
Rosiglitazone
STENO-2
SYNCHRONY
HbA1c
SYNTAX
T2D
Glucose
T2DM
Tesaglitazar
Thiazolidinediones
triglyceride
Triglyceride/HDL-C
TRITON–TIMI 38
Type 2 Diabetes
TZD
Vascular Wall Disease